CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(04): 191-194
DOI: 10.1055/s-0041-1723108
Original Article: Bone and Soft Tissue Tumor

Outcomes of Adult Ewing Sarcoma Treated with Multimodality Therapy: A Single-Institute Experience

Ravi Chandran
1  Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Siva Prasad Kuruva
1  Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Rachana Chennamaneni
1  Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Stalin Bala
1  Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Meher Lakshmi Konatam
1  Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Sadashivudu Gundeti
1  Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
› Author Affiliations

Abstract

Introduction Ewing sarcoma (ES) is more common in children and relatively rare in adults. Adult ES has poor prognosis than children. Treatment approaches for adults have been extrapolated from pediatric experience. Data on adult ES are very few because of its rarity in adults. The present study was done to analyze the clinical profile and outcome of adult ES.

Aims The aim was to study the clinical and pathological treatment and outcomes in adult ES.

Subjects and Methods Between 2010 and 2017, a total of 73 ES patients with age more than 18 years were retrospectively analyzed. Survival analysis was done by plotting Kaplan–Meier curves.

Results A total of 73 patients were diagnosed with ES during 2010 to 2017. Among them, 43 (58.9%) had localized disease with a median age of 24.5 years. Males were 44 (60.3%) and females were 29 (39.7). Pain (75.3%) was the most common symptom at presentation. Nine patients had incomplete details and were excluded from the analysis. Among 21 (28.8%) patients, the lung (61.9%) was the most common site of metastasis followed by the bone, bone marrow, and brain. The median number of chemotherapy cycles in the localized disease was 14 (range 1–17), and in metastatic disease, it was 4 (range 1–7). Univariate analysis was done with respect to age (< 25 vs. ≥25), gender, elevated or normal serum lactate dehydrogenase level, tumor size (< 8 cm versus ≥8 cm), site (axial versus extremity), and neoadjuvant chemotherapy (NACT) given or not. NACT had a significant impact on overall survival (OS) and the rest had no effect. At a median follow-up of 40 months, the 3-year OS in localized disease was 87.4%. In metastatic disease, the median OS was 13 months with 3-year OS of 26%.

Conclusions Outcomes with multimodality therapy in adult ES patients with localized disease are comparable to that of a pediatric cohort. However, metastatic disease has poor survival.



Publication History

Publication Date:
04 July 2021 (online)

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India